Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 362 (2) , 362-369
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and NeckTranslational Oncology, 2014
- A Critical Role of the PTEN/PDGF Signaling Network for the Regulation of Radiosensitivity in Adenocarcinoma of the ProstateInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 PathwayPLOS ONE, 2013
- MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTENCell Cycle, 2012
- E-Cadherin loss associated with EMT promotes radioresistance in human tumor cellsRadiotherapy and Oncology, 2011
- Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponseRadiotherapy and Oncology, 2010
- Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation TherapyJournal of Clinical Oncology, 2010
- Cyclooxygenase-2 Inhibitor NS398 Enhances Radiosensitivity of Radioresistant Esophageal Cancer Cells by Inhibiting AKT Activation and Inducing ApoptosisCancer Investigation, 2010
- Reverse resistance to radiation in KYSE-150R esophageal carcinoma cell after epidermal growth factor receptor signal pathway inhibition by cetuximabRadiotherapy and Oncology, 2009
- Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiationCancer Gene Therapy, 2004